Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287684
Status:
RECRUITING
Last Update Posted:
2024-03-01
First Post:
2024-02-22
Brief Title:
Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis
Sponsor:
Mater Dei Hospital Malta
Organization:
Mater Dei Hospital Malta
Study Overview
Official Title:
Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MENDSEP
Brief Summary:
Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection No drug specifically targeting sepsis has been approved The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit or be harmed from specific therapeutic interventions Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular endotypes or subclasses with important clinical implications Classifying sepsis patients as molecular endotypes revealed that a poor prognosis endotype was characterized by immunosuppression and septic shock Against this backdrop the study hypothesis is that a poor prognosis for sepsis is defined by a molecular endotype reflecting impaired innate immune and endothelial barrier integrity in the primary anatomical site of infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None